<DOC>
	<DOCNO>NCT02662894</DOCNO>
	<brief_summary>Noninferiority trial ass efficacy fixed-dose combination valsartan + rosuvastatin versus isolate component treatment hypertension dyslipidemia .</brief_summary>
	<brief_title>Fixed-dose Combination Valsartan + Rosuvastatin Versus Their Isolated Components Hypertension Dyslipidemia .</brief_title>
	<detailed_description>- Open-label , randomize , multicenter ; - Maximal experiment duration : 8 week ; - 04 visit ; - Safety efficacy evaluation</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Participants sex age 18 65 year ; Participants diagnose uncontrolled hypertension ; Participants intermediate high risk dyslipidemia , accord V Brazilian Guidelines Dyslipidemia Prevention Atherosclerosis ; Ability understand consent participate clinical study , manifest signing Informed Consent Informed ( IC ) . Participants previous diagnosis familial hypercholesterolemia ( homozygous ) ; Concomitant use angiotensin II receptor blocker ( ARB ) inhibitor angiotensin convert enzyme ( ACE ) ; participant isolate hypertriglyceridemia ( TG ≥150 mg / dL ) accord V Brazilian Guidelines Dyslipidemia Prevention Atherosclerosis ; research participant total cholesterol ( TC ) 500 mg / dL triglyceride ( TG ) 400 mg / dL ; participant systolic blood pressure ≥180 mmHg diastolic ≥110 mmHg ; research participants postural hypotension ( SBP decrease ≥20 mmHg DBP ≥10 mmHg orthostatic position relation sit position ) ; History congestive heart failure ( CHF ) functional class III IV ( NYHA ) ; ; clinical , laboratory electrocardiographic , judgment investigator , may interfere safety research participant ; Creatine phosphokinase ( CPK ) level establish laboratory normal range ; Transaminases ( ALT ASL ) serum 2 time establish laboratory normal range ; Body mass index ( BMI ) ≥35 kg / m² ; Immunocompromised participant ( eg . : malignancy , patient Acquired Immunodeficiency Syndrome etc ) ; Chronic use drug may interact drug study ; Patients concomitant lipidlowering therapy ; History hypersensitivity active ingredient use study ; Participants pregnant , nurse plan become pregnant , female participant childbearing potential use reliable method contraception ; History alcohol abuse illicit drug use ; Adherence uniformization medication &lt; 80 % ; Participating research participate clinical trial protocol last twelve ( 12 ) month ( CNS Resolution 251 August 7 , 1997 , Part III , subitem J ) , unless investigator considers may direct benefit ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>